Drug Trial Radar · NCT06122610
Using Novel Imaging to More Safely Treat Neuroendocrine Tumors
Last checked: Nov 20, 2026Latest source record: Jun 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
4
Actual
Start
Mar 7, 2025
Primary completion
May 31, 2026
Study completion May 31, 2026
Sponsor
- Lead sponsor
- University of Wisconsin, MadisonAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 8, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this research is to determine if DetectnetTM PET/CT can be used to make Lutathera therapy safer for patients with neuroendocrine cancer. Participants will: * Complete two phases involving 6 visits * Undergo additional research PET/CT, and possibly SPECT/CT scans
Conditions
- Neuroendocrine Tumors
- Somatostatin Receptor-positive Neuroendocrine Tumor
Interventions
Single Photon Emission Computed Tomography/ Computed Tomography (SPECT/CT)Device
SPECT/CT will be performed after first cycle of Lutathera® treatment
Photon Emission Tomography / CT (PET/CT)Device
PET/CT will be performed after 64Cu-DOTATATE and Lutathera® treatment
64Cu-DotatateDrug
Standard of care administration of radioactive drug for PET/CT
177Lu-DotatateDrug
Standard of care administration of radioactive drug for PET/CT and SPECT/CT
Primary outcomes
What the sponsor says the trial is designed to measure.
- Compare pre-therapy and post-therapy voxel-based dosimetry estimatesTime frame: Baseline and 120 hours post-dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Wisconsin - Madison
Madison, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.